Research & IP · United States

Gilead Sciences

Leading antiviral developer: remdesivir (Veklury) for COVID-19, HIV regimens and the twice-yearly lenacapavir HIV prevention injection, plus the Yescarta CAR-T therapy via Kite.

Headquarters
Foster City, California, United States · North America
Value chain
Research & IP(Research & design)
What that means
Invents and licenses: corporate and contract research, IP and technology licensing, with little production of its own.
Founded
1987
Staff
17,600 (2024)
Ownership
Listed
Listing
Nasdaq:GILD on Google Finance
Website
gilead.com
Relevance
High at its strongest, in Advanced Therapeutics, Vaccines & Medical Countermeasures

In 1 capability

Each capability the company is listed in, most relevant first: how experts in the field see its global relevance there, why it is listed and the source.

  1. Biotechnology & Health Technologies · Design · listed #11 of 50

    Leading antiviral developer: remdesivir (Veklury) for COVID-19, HIV regimens and the twice-yearly lenacapavir HIV prevention injection, plus the Yescarta CAR-T therapy via Kite.

    Relevance: Leading antiviral developer

    Source · en.wikipedia.org